Target Price | $6.63 |
Price | $1.29 |
Potential |
413.57%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target Esperion Therapeutics, Inc. 2026 .
The average Esperion Therapeutics, Inc. target price is $6.63.
This is
413.57%
register free of charge
$16.00
1,140.31%
register free of charge
$2.00
55.04%
register free of charge
|
|
A rating was issued by 8 analysts: 6 Analysts recommend Esperion Therapeutics, Inc. to buy, 1 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Esperion Therapeutics, Inc. stock has an average upside potential 2026 of
413.57%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 332.31 | 343.95 |
185.66% | 3.50% | |
EBITDA Margin | 16.39% | 4.99% |
112.27% | 69.56% | |
Net Margin | -16.50% | 2.14% |
95.17% | 112.97% |
8 Analysts have issued a sales forecast Esperion Therapeutics, Inc. 2025 . The average Esperion Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Esperion Therapeutics, Inc. EBITDA forecast 2025. The average Esperion Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Esperion Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Esperion Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.28 | 0.04 |
86.21% | 114.29% | |
P/E | 34.40 | |
EV/Sales | 2.04 |
4 Analysts have issued a Esperion Therapeutics, Inc. forecast for earnings per share. The average Esperion Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Esperion Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 11 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Feb 11 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 20 2025 |
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Mar 05 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 04 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 11 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Feb 11 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Jan 23 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 23 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.